93742-85-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoro-1-tetralone is used as a building block for the synthesis of various pharmaceutical compounds, due to its unique reactivity and structural properties. It can be incorporated into the development of new drugs, potentially leading to improved therapeutic effects and reduced side effects.
Used in Organic Synthesis:
5-Fluoro-1-tetralone is used as an intermediate in the synthesis of complex organic molecules, particularly in the field of medicinal chemistry. Its fluorinated structure allows for the creation of new compounds with altered properties, which can be further explored for their potential applications in various industries.
Used in Research and Development:
5-Fluoro-1-tetralone is used as a research compound in academic and industrial laboratories, where its unique properties can be studied and utilized in the development of new chemical processes and methodologies. This can lead to advancements in the fields of chemistry, materials science, and related disciplines.

InChI:InChI=1/C10H9FO/c11-9-5-1-4-8-7(9)3-2-6-10(8)12/h1,4-5H,2-3,6H2

Upstream product

• 143654-62-0 4-(2-Fluorophenyl)butanoic acid 
• 166251-26-9 4-(2-fluorophenyl)butyryl chloride 
• 96-48-0 4-butanolide 
• 462-06-6 fluorobenzene 
• 450-95-3 2-fluoroacetophenone 
• 1058086-76-2 (E)-4-(2'-fluorophenyl)-4-oxobut-2-enoic acid 
• 445-27-2 2'-Fluoroacetophenone 
• 348-52-7 1-Fluoro-2-iodobenzene 
• 911825-55-3 methyl 4-(2-fluorophenyl)butanoate 
• 51114-94-4 (2-carboxyethyl)triphenylphosphonium bromide 
• 127404-67-5 4-(3-fluoro-phenyl)-but-3-enoic acid 
• 69797-46-2 4-(3'-fluorophenyl)-4-oxo-butanoic acid 
• 70631-88-8 4-(3-fluorophenyl)butanoic acid 

Downstream Products

• 145485-58-1 6-fluoro-1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one 
• 911825-56-4 5-fluoro-3,4-dihydronaphthalen-1(2H)-one oxime 
• 907973-43-7 5-fluoro-1,2,3,4-tetrahydronaphthalen-1-amine 
• 911825-56-4 (Z)-5-fluoro-3,4-dihydronaphthalen-1(2H)-oxime 

Relevant academic research and scientific papers

KRAS G12C INHIBITORS AND USES THEREOF

The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.

Synthesis of Novel Pterocarpen Analogues via [3?+?2] Coupling-Elimination Cascade of α,α-Dicyanoolefins with Quinone Monoimines

By employing triethylamine as a catalyst, [3?+?2] coupling-elimination cascade of α,α-dicyanoolefins with quinone monoimines was realized. The reactions afforded various novel pterocarpen analogues with generally moderate yields (up to 75%). In addition, a plausible reaction mechanism was proposed.

Highly enantioselective [3+2] coupling of cyclic enamides with quinone monoimines promoted by a chiral phosphoric acid

Enantioselective [3+2] coupling of cyclic enamides with quinone monoimines was realised using a chiral phosphoric acid as a catalyst. This transformation allowed for the synthesis of highly enantioenriched polycyclic 2,3-dihydrobenzofurans (up to 99.9% ee). The absolute configuration of one product was determined by an X-ray crystal structural analysis. We also found a possible mechanism for this reaction.

Enantioselective halogenative semi-pinacol rearrangement: Extension of substrate scope and mechanistic investigations

The present Full Paper article discloses a survey of our recent results obtained in the context of the enantioselective halogenation-initiated semi-pinacol rearrangement. Commencing with the fluorination/semi-pinacol reaction first and moving to the heavier halogens (bromine and iodine) second, the scope and limitations of the halogenative phase-transfer methodology will be discussed and compared. An extension of the fluorination/semi-pinacol reaction to the ring-expansion of five-membered allylic cyclopentanols will be also described, as well as some preliminary results on substrates prone to desymmetrization will be given. Finally, the present manuscript will culminate with a detailed mechanistic investigation of the canonical fluorination/semi-pinacol reaction. Our mechanistic discussion will be based on in situ reaction progress monitoring, complemented with substituent effect, kinetic isotopic effect and non-linear behaviour studies.

Enantioselective organocatalytic fluorination-induced Wagner-Meerwein rearrangement

Cracked under strain: Strained allylic cyclobutanols and cyclopropanols readily undergo a ring expansion described by the title rearrangement. This reaction is promoted by catalytic amounts of 1 and displays high tolerance with respect to the substrate scope. The corresponding β-fluoro spiroketone products are isolated in high yields and with excellent stereoselectivities. EDG=electron-donating group, EWG=electron-withdrawing group. Copyright

SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).

BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I) wherein each symbol is as defined

7-Substituted Purine Derivatives for Immunosuppression

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III:

7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula (III).

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS

Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.